Market capitalization | $9.52m |
Enterprise Value | $32.50m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 3.10 |
P/S ratio (TTM) P/S ratio | 0.91 |
P/B ratio (TTM) P/B ratio | 0.79 |
Revenue growth (TTM) Revenue growth | -2.25% |
Revenue (TTM) Revenue | $10.48m |
EBIT (operating result TTM) EBIT | $-29.86m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Jaguar Health, Inc.:
1 Analyst has issued a forecast Jaguar Health, Inc.:
Sep '24 |
+/-
%
|
||
Revenue | 10 10 |
2%
2%
|
|
Gross Profit | 6.04 6.04 |
15%
15%
|
|
EBITDA | -28 -28 |
10%
10%
|
EBIT (Operating Income) EBIT | -30 -30 |
10%
10%
|
Net Profit | -38 -38 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
Head office | United States |
CEO | Lisa Conte |
Employees | 49 |
Founded | 2013 |
Website | www.jaguar.health |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.